Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay

References

• Acharya S, Sahoo SK. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63:170–83
   PubMed Web of Science ®Google Scholar
• Arnold RD, Slack JE, Straubinger RM. (2004). Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B 808:141–52
   PubMed Web of Science ®Google Scholar
• Bibby DC, Talmadge JE, Dalal MK, et al. (2005). Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293:281–90
   PubMed Web of Science ®Google Scholar
• Chen CL, Thoen KK, Uckun FM. (2001). High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors. J Chromatogr B 764:81–119
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie SM, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–16
   PubMed Web of Science ®Google Scholar
• DiFrancesco R, Griggs JJ, Donnelly J, et al. (2007). Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 852:545–53
   PubMed Web of Science ®Google Scholar
• Dong YF, Xie H, Guo Y, et al. (2008). Biocompatibility of poly(3-hydroxybutyrate-co-hydroxyocatanoate). J Clin Reh Tissue Eng Res 12:1870–2
   Google Scholar
• Guo Y, Dong YF, Chen Z, et al. (2009). Study of P(HB-HO) as scaffold for bone tissue engineering. J Funct Mater 3:459–66
   Google Scholar
• Harris L, Batist G, Belt R, et al. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25–36
   PubMed Web of Science ®Google Scholar
• Hu FQ, Liu LN, Du YZ, et al. (2009). Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials 30:6955–63
   PubMed Web of Science ®Google Scholar
• Hu T, Le QH, Wu ZY, et al. (2007). Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-β-hydroxybutyrate microspheres. J Pharm Biomed 43:263–9
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, et al. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26:492–501
   PubMed Web of Science ®Google Scholar
• Kim HS, Wainer IW. (2010). Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence. J Pharm Biomed 52:372–6
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Bátkai S, et al. (2009). Role of superoxide, nitric oxide, and neroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol-Heart C 296:H1466–83
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–25
   PubMed Web of Science ®Google Scholar
• Ogawara K, Un K, Minato K, et al. (2008). Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. Int J Pharm 359:234–40
   PubMed Web of Science ®Google Scholar
• Oh I, Lee K, Kwon HY, et al. (1999). Release of adriamycin from poly(γ-benzyl-L-glutamate)/poly(ethylene oxide) nanoparticles. Int J Pharm 181:107–15
   PubMed Web of Science ®Google Scholar
• Tan EC, Lin R, Wang CH. (2005). Fabrication of double-walled microspheres for the sustained release of doxorubicin. J Colloid Interface Sci 291:135–43
   PubMed Web of Science ®Google Scholar
• Wang JC, Liu XY, Lu WL, et al. (2006). Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm 62:44–51
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. (2004). Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 96:273–83
   PubMed Web of Science ®Google Scholar
• Zhang C, Dong YF, Zhao LQ. (2014). Preparation and characterization of novel microparticles based on poly (3-hydroxybutyarte-co-3-hydroxyoctanoate). J Microencapsul 31:9–15
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao LQ, Dong YF, et al. (2010). Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm 76:10–16
   PubMed Web of Science ®Google Scholar
• Zhang ZP, Lee SH, Feng SS. (2007). Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28:1889–99
   PubMed Web of Science ®Google Scholar
• Zhao LQ, Xiao JF, Feng T, et al. (2006). Synthesis of poly (3-hydroxybutyrate-co-3-hydroxyoctanoate) by a Sinorhizobium fredii strain. Lett Appl Microbiol 42:344–9
   PubMed Web of Science ®Google Scholar